TPPTM Protease 375K is a proprietary blend of highly active proteolytic enzymes with a wide range of pH stability. Proteolytic enzymes taken orally under certain conditions have been shown to be absorbed in substantial quantities into the blood. Once in the blood circulation, the enzymes in this blend bind to serum proteins, particularly alpha 2-macroglobulin (a2M), and impart immunomodulatory benefits. One of the best-established functions served by the oral proteases in TPPTM blend is in the maintenance of normal blood flow. This is accomplished by breaking down blood clots (fibrinolysis) and platelet aggregation within blood vessels and breaking down excess extra-vascular plasma proteins as in edema. TPPTM Protease 375K will also enhance the hydrolysis of food proteins for enhanced bio-availability of amino acids.
When taken on an empty stomach, it should be noted that protease is readily taken up into the mucosa cells of the intestine and passed into blood circulation. Clinical observations have noted that upon high intake of TPPTM Protease 375K, heavy metal concentrations have been significantly decreased in the blood. COMPONENT BENEFITS:
TzymeTM Protease Blend in TPPTM Protease provides vital systemic benefits that include support of adequate blood rheology for optimum flow of immune cells, their meditating molecules, hormones, blood cells and other vital molecules and cells. The superb absorption abilities and high functionality of this product are certain to enhance and optimize overall protein hydrolysis. These benefits, in turn, facilitate and support a wide array of metabolic processes.
TPPTM Protease 375K benefits include:
MODULATION OF THE IMMUNE SYSTEM
As a result of their coupling to a2M, Tzymeô proteolytic enzymes exhibit an increased binding of several very important cytokines (hormones-like molecules which have a powerful influence on immune cells) such as Transforming growth factor-beta (TGF-b), and Tumor Necrosis Factor-alpha (TNF-a). Studies have indicated that oral hydrolytic enzymes affect cytokine synthesis and modulatory effects. For instance, TNF-a synthesis, which is a necessary step in host defense against tumor cells, is impaired when experimentally inactivated oral proteolytic enzymes were used.
Thus, active, GI stable and functional oral enzymes that are absorbed in the blood stream can provide therapeutic applications. In addition, studies have shown that oral proteolytic enzymes increased the tumoricidal and cytotoxic activities of polymorphonuclear neutrophils.
Several hypotheses have been put forth as to the mechanisms by which proteolytic enzymes modulate the immune system to control and eliminate tumors. Some studies indicated that proteolytic enzymes selectively remove some adhesion molecules such as CD4, CD44, B7-1, ICAM-1, B7-2, CD45RA, CD6, CD7, E2/MIC2, and Leu81/LAM 1 from cell surfaces According to Hale et al. the removal of these surface molecules has markedly enhanced CD2 mediated T-cell activity.
Some studies have implied that by removing the glycoprotein CD44, some proteases help control the tumor growth of certain types of cells. This selective removal of some mediator proteins, and the regulation of cytokines constitute some factors by which proteolytic enzymes are thought to modulate the immune system and act as biological response modifiers."